Amphastar Pharma (AMPH) Misses Q2 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- Tech stocks power S&P 500 to record high as oil, producer inflation weaken
- Oil falls more than 3% on weaker global demand outlook and US crude buildup
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2018
August 8, 2018 4:05 PM EDTReports Net Revenues of $71.0 Million for the Three Months Ended June 30, 2018
RANCHO CUCAMONGA, Calif., Aug. 08, 2018 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (Amphastar or the Company) today reported results for the three months ended June 30, 2018.
Second Quarter Highlights
Net revenues of $71.0 million for the second quarterGAAP net loss of $2.8 million, or $0.06 per diluted share, for the second quarterAdjusted non-GAAP net income of $1.2 million, or $0.03 per diluted share, for the second quarterDr. Jack Zhang, Amphastars CEO, commented: We had an exciting three months with FDA... More
